KDIGO 2024 慢性肾脏病评估与管理临床实践指南执行摘要
KDIGO 2024 慢性肾脏病指南更新了 2012 版,基于更广泛证据、采用 GRADE 方法制定,涵盖 CKD 评估与风险分层、延缓进展与并发症管理、用药管理及优化照护模式,不适用于透析或肾移植患者。
要点
- 指南适用于未接受透析或肾移植的 CKD 患者。
- 推荐基于系统评价与 GRADE 证据分级。
- 涵盖评估、延缓进展、用药管理与照护模式。
核心结论
- KDIGO 2024 CKD 指南基于更广泛证据更新,为 CKD 评估与管理提供推荐。
研究设计与样本
- 由 KDIGO 组织患者伙伴、临床医生和研究人员采用稳健方法制定,基于系统评价和 GRADE 分级。
主要发现
- 新疗法和策略已在大型多样人群中测试,有助于指导照护。
- 指南关注国际考量、全生命周期 CKD 及实施中的特殊考虑。
关键数值与推荐
- 推荐条款基于相关研究的系统评价及证据质量和推荐强度评估。
临床怎么用
- 指南提供实践要点以指导未进行系统评价的临床照护或活动。
- 包含有用信息图表并描述未来重要研究议程。
局限性
- 指南不适用于接受透析或肾移植的患者。
- 证据局限性在指南中有所讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment.
引用
- Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024. PMID: 38519239. doi:10.1016/j.kint.2023.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。